"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 8 | 12 |
| 1996 | 5 | 3 | 8 |
| 1997 | 8 | 3 | 11 |
| 1998 | 12 | 4 | 16 |
| 1999 | 4 | 6 | 10 |
| 2000 | 7 | 6 | 13 |
| 2001 | 6 | 5 | 11 |
| 2002 | 11 | 15 | 26 |
| 2003 | 10 | 16 | 26 |
| 2004 | 12 | 12 | 24 |
| 2005 | 19 | 14 | 33 |
| 2006 | 20 | 14 | 34 |
| 2007 | 19 | 20 | 39 |
| 2008 | 16 | 15 | 31 |
| 2009 | 16 | 7 | 23 |
| 2010 | 18 | 12 | 30 |
| 2011 | 16 | 15 | 31 |
| 2012 | 13 | 12 | 25 |
| 2013 | 19 | 9 | 28 |
| 2014 | 19 | 6 | 25 |
| 2015 | 20 | 10 | 30 |
| 2016 | 18 | 10 | 28 |
| 2017 | 29 | 19 | 48 |
| 2018 | 26 | 13 | 39 |
| 2019 | 20 | 7 | 27 |
| 2020 | 26 | 16 | 42 |
| 2021 | 19 | 21 | 40 |
| 2022 | 4 | 26 | 30 |
| 2023 | 7 | 31 | 38 |
| 2024 | 9 | 22 | 31 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
-
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 Mar 01; 5(3):527-548.
-
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations. Neuro Oncol. 2025 Feb 10; 27(2):352-368.
-
Characterization of Rationally Designed CRISPR/Cas9-Based DNA Methyltransferases with Distinct Methyltransferase and Gene Silencing Activities in Human Cell Lines and Primary Human T Cells. ACS Synth Biol. 2025 Feb 21; 14(2):384-397.
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
-
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Nat Cancer. 2025 Jan; 6(1):123-144.
-
Monoallelic expression can govern penetrance of inborn errors of immunity. Nature. 2025 Jan; 637(8048):1186-1197.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. J Immunother Cancer. 2024 Dec 25; 12(12).
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).